COMBINING
UNCOMMON EXPERTISE
WITH PROPRIETARY DATA
TO DRIVE UNIQUE INSIGHT
IPD Analytics identifies, projects, and quantifies the impact of competitive-landscape shifts in the pharmaceutical and biologic market to offer:
-
Industry-leading drug life-cycle analysis
-
Clinical, formulary, procurement, and inventory-control insights for payers, providers, and suppliers
-
Brand and generic market impact forecasts
-
Pharmaceutical coding and reimbursement information
THE INDUSTRY LEADER
AN INDEPENDENT, THIRD-PARTY SOURCE
We take data from thousands of sources, combine it with proprietary research, and work to normalize, analyze, and summarize...
With a unique team of experts, including:
Former Federal Circuit Patent Clerks and Litigators
Payor and Provider
Clinical Pharmacists
Brand and Generic Financial Forecasters from
Major Manufacturers
PhD Scientists with Pharmacy and Bioscience Backgrounds
Team of Researchers and Patent Searchers Utilizing Proprietary Data Aggregation Tools
We develop the
foundation that powers our solutions:
loss-of-exclusivity
timing
And provide meaningful, tailored insights for
specific use cases:
Key Litigation Updates & Analysis
Critical Headlines &
Day-by-day Trial Updates
Drug & Disease-Class Reviews
Formulary Planning Guidance
Loss-of-Exclusivity and
Market-Impact Forecasts
Analog Library with Accompanying Qualitative Analysis
Pipeline-Planning Tools
Coding & Reimbursement Insights
Drug-Price Tools
Scenario Analysis
We deliver these insights in multiple, easily consumable formats:
To serve stakeholders and institutional investors across the pharmaceutical industry:
Platform
Email Alerts
Direct Consultations
Podcast Episodes
Reports
Data Downloads
Manufacturers:
Brand Manufacturers
Generic Manufacturers
Specialty Drug Manufacturers
Active Ingredient Manufacturers
Institutional Investors:
Investment Managers
Hedge Funds
Mutual Funds
Sovereign Funds
Pension Funds
THE INDUSTRY LEADER
AN INDEPENDENT, THIRD-PARTY SOURCE
Since 2002, IPD Analytics has offered solutions that:
-
Deliver compelling insight and unique data assets to solve complex, multi-layered problems
-
Enable efficiency and transparency in an opaque pharmaceutical market
-
Offer a comprehensive look at the past to help predict future market shifts
We take data from thousands of sources, combine it with proprietary research, and work to normalize, analyze, and summarize...
With a unique team of experts, including:
Former Federal Circuit Clerks, Patent Attorneys, and Litigators
Payer and Provider
Clinical Pharmacists
Brand and Generic Financial Forecasters from
Major Manufacturers
PhD Scientists with Pharmacy and Bioscience Backgrounds
Team of Researchers and Patent Searchers Utilizing Proprietary Data-Aggregation Tools
We develop the
foundation that powers our solutions:
loss-of-exclusivity
timing and innovative, product-launch tracking
And provide meaningful, tailored insights for
specific use cases:
Drug Litigation Updates & Analysis
Critical Headlines &
Day-by-Day Trial Updates
Drug & Disease-Class Reviews
Formulary Planning Guidance
Loss-of-Exclusivity and
Market-Impact Forecasts
Clinical Pipeline Tracking Tools
Coding & Reimbursement Solutions
Drug-Price and Rebate Monitoring Tools
Limited Distribution, Formulary Coverage, Clinical Criteria, and Therapy Cost Analysis
Brand, Generic, and Biosimilar Launch Forecasts
Budget Impact Models
We deliver these insights in multiple, easily consumable formats:
To serve stakeholders and institutional investors across the pharmaceutical industry:
Online Platform
Email Alerts
Phone Consultations
Podcast Episodes
Reports
Data Downloads
Manufacturers:
Brand Manufacturers
Generic Manufacturers
Specialty-Drug Manufacturers
Active-Ingredient Suppliers
Payors, Providers, & Suppliers:
Payors
Health Systems
Wholesalers
Specialty & Retail Pharmacies
Long-Term Care Facilities
IDNs
GPOs
PBMs
Institutional Investors:
Investment Managers
Hedge Funds
Mutual Funds
Sovereign Funds
Pension Funds
Private Equity
OUR SOLUTIONS
IPD Analytics provides actionable insights to drive decisions.
We offer subscription-based access to our proprietary platforms, consultations, real-time email alerts, comprehensive reports, data downloads, podcast episodes, and more.
Pharmaceuticals | Biotech | Biosimilars
Global Life-Cycle Solutions
Clinical Pharmacy Solutions
Market Forecasting Solutions
OTHER INDUSTRIES
OUR SUBSCRIBERS
IPD Analytics offers tech-enabled solutions to stakeholders across the pharmaceutical landscape.
PODCAST
IPD's Drug & Clinical Review:
The Premier Podcast for Drug Intelligence and Management Strategy
Within each episode, IPD's Executive Clinical Pharmacy Team discusses:
-
Drug pipeline intelligence and clinical strategy surrounding loss of exclusivity, high-cost and complex drugs, formulary planning, and pharmacy and therapeutics management
-
Impactful generic, brand, and biosimilar launches coming
down the pipeline
-
Strategies to improve outcomes, lower pharmacy spend, and optimize formulary design
-
Popular questions frequently asked by payers, providers, and manufacturers around the country
NEWSROOM
FEATURED
REPORT FEATURE
April 21, 2020
National trends in prescription drug expenditures and projections for 2021
Purpose
To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2021 in the United States, with a focus on the nonfederal hospital and clinic sectors.
Methods
Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2021 were reviewed—including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for biosimilars, cancer drugs, generics, coronavirus disease 2019 (COVID-19) pandemic influence, and specialty drugs. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2021 were based on a combination of quantitative analyses and expert opinion.
SEE MORE
ARTICLE FEATURE
April 21, 2020
Further Dissecting the Launch of Adalimumab Biosimilars in the US
As we inch closer to the January 2023 date for the launch of the first US adalimumab biosimilar, industry watchers are more closely scrutinizing which company, if any, will have a competitive advantage in this lucrative marketplace.
Just to reset, the series of settlements signed by AbbVie currently puts Amgen’s Amjevita® first to be released, followed by several others according to the schedule we first published in May 2019.
A few developments have occurred since then, primarily the subsequent FDA approval of Hulio®, Hadlima®, and Abrilada®. Momenta was acquired by Johnson & Johnson in October 2020 and is no longer a separate entity or operating in the biosimilar business. But Coherus filed for approval in December 2020, and Alvotech and its partner Teva filed in November 2020. Celltrion, which completed its phase 3 trial, is on the verge of filing for approval, and Fresenius Kabi may join the crowd in filing this year as well.
SEE MORE
ARTICLE FEATURE
October 8, 2020
EY Announces Howard Krass founder and CEO of IPD Analytics, LLC as Entrepreneur Of The Year® 2020 Florida Award Winner
Ernst & Young LLP (EY US) today announced that Howard Krass of IPD Analytics, LLC was named an Entrepreneur Of The Year® 2020 Florida Award winner. The Entrepreneur Of The Year Awards program is one of the preeminent competitive awards for entrepreneurs and leaders of high-growth companies. Howard was recognized for his excellence in innovation, societal impact, commitment to building a values-based company, financial performance, and overall leadership. Howard Krass was selected by an independent judging panel. The award was announced through the program’s first-ever virtual awards gala, hosted by Deborah Norville, anchor of Inside Edition, on October 8, 2020. To watch the replay, visit the Florida program website.